Prior Reported, ESSA Pharma Presents Data on Prostate Cancer Therapy Masofaniten at ESMO 2024, Shows Prolonged PSA Reduction
Portfolio Pulse from Benzinga Newsdesk
ESSA Pharma presented promising data on its prostate cancer therapy, masofaniten, at the ESMO 2024 Congress. The Phase 1/2 study shows prolonged PSA reduction when combined with enzalutamide, with no median time to PSA progression reached after 15.2 months.
September 16, 2024 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ESSA Pharma's presentation at ESMO 2024 highlights promising data for masofaniten in prostate cancer treatment, showing prolonged PSA reduction and favorable comparison to enzalutamide alone.
The presentation of positive data at a major oncology conference like ESMO can boost investor confidence in ESSA Pharma's pipeline, potentially leading to a positive short-term impact on EPIX stock. The data shows masofaniten's effectiveness in combination with enzalutamide, which could enhance its market potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100